#### INDEVUS PHARMACEUTICALS INC

Form 4

December 08, 2008

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**OMB** 

Check this box if no longer

Washington, D.C. 20549

3235-0287 Number: January 31,

**OMB APPROVAL** 

subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Expires: 2005 Estimated average burden hours per

0.5

Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

response...

30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **ROGERS MICHAEL W** 

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

INDEVUS PHARMACEUTICALS INC [IDEV]

(Check all applicable)

(Last) (First) (Middle)

(Street)

3. Date of Earliest Transaction

Director 10% Owner \_X\_\_ Officer (give title Other (specify

(Month/Day/Year) 33 HAYDEN AVENUE 12/04/2008

below) below) **Executive Vice President** 

4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

(Instr. 4)

6. Individual or Joint/Group Filing(Check

Person

LEXINGTON, MA 02421

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year)

Execution Date, if

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D)

5. Amount of Securities Beneficially Owned

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial Ownership (T)

(Instr. 4)

(Instr. 3, 4 and 5) (Month/Day/Year) (Instr. 8)

Following Reported Transaction(s)

(Instr. 3 and 4)

Code V Amount (D) Price

(A)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Conversion Security or Exercise

3. Transaction Date 3A. Deemed (Month/Day/Year)

Execution Date, if any

4. 5. Number of TransactiorDerivative Securities Code Acquired (A) or

6. Date Exercisable and **Expiration Date** (Month/Day/Year)

7. Title and Amou Underlying Secur (Instr. 3 and 4)

#### Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Disposed of (Instr. 3, 4,					
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Am Nur Sha
Stock Option (Right to Buy)	\$ 6	12/04/2008		D <u>(1)</u>		125,000	(2)	10/05/2009	Common Stock, \$.001 par value per share	12
Stock Option (Right to Buy)	\$ 6	12/04/2008		A <u>(1)</u>	125,000		(3)	10/05/2010	Common Stock, \$.001 par value per share	12
Stock Option (Right to Buy)	\$ 4	12/04/2008		D <u>(1)</u>		250,000	(2)	10/05/2009	Common Stock, \$.001 par value per share	25
Stock Option (Right to Buy)	\$ 4	12/04/2008		A(1)	250,000		(3)	10/05/2010	Common Stock, \$.001 par value per share	25

## **Reporting Owners**

Reporting Owner Name / Address			Relationships		
	Director	10% Owner	Officer	Other	
ROGERS MICHAEL W					

33 HAYDEN AVENUE LEXINGTON, MA 02421

**Executive Vice President** 

## **Signatures**

Michael W.
Rogers

\*\*Signature of Date

\*\*Signature of D Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- All of the reported transactions involved the amendment of outstanding stock options to extend the respective expiration dates from (1) 10/5/2009 to 10/5/2010; such extensions are considered by the Securities and Exchange Commission to be cancellations of the current stock options.

Reporting Owners 2

### Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form 4

- (2) Prior to the extension of the current stock option, such stock option was fully exercisable.
- (3) This stock option is fully exercisable as of the date of this report.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.